Antitrust: Commission sends Statement of Objections to Teva over misuse of the patent system and disparagement of rival multiple sclerosis medicine* The European Commission has informed Teva of its preliminary view that the company has breached EU antitrust rules by engaging in practices intended to delay competition to its blockbuster medicine, Copaxone. These consisted in artificially extending patent protection of Copaxone and by systematically spreading misleading information about a competing product with a view to hinder its market entry and uptake. Executive Vice-President Margrethe Vestager, in charge of competition policy, said: "Until today, there is not yet a treatment for the chronic illness of multiple sclerosis. So innovative medicines can make a major difference to
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.